Precision oncology can guide treatment selection and treatment omission in older adults, but molecular actionability alone does not establish an acceptable individual benefit-burden balance. This focused narrative review examines tumor biology, host vulnerability, and implementation barriers, prioritizing randomized tr...
PURPOSE
The relationship between the number of initial metastases and metastatic spread in terms of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (mBC) remains poorly understood. This study aimed to identify key factors influencing disease progression and survival from the first...
Fran-ziska Albrecht, Martin Heidinger, T. Zwimpfer et al.· Cancer Treatment and Researc...· 0 citations
Immunohistochemistry (IHC) of ER, PR, HER2, and Ki67 are established prognostic and predictive markers in breast cancer. Gene expression assays such as PAM50 and Oncotype DX are increasingly used for molecular subtyping and recurrence risk calculation. The APIS Breast Cancer Subtyping Kit (BCSK) quantitatively measures...
T. Wallrabenstein, E. Chiru, M. Sonderegger et al.· Current Issues in Molecular...· 0 citations
It is shown that breast cancer metastases differ in their capacity for secondary seeding: the liver fosters metastasis-promoting properties and boosts secondary spread, whereas the lung restricts these processes, favoring local growth.
Magdalena K. Sznurkowska, Francesc Castro-Giner, Irene D'Anna et al.· Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.